How should I evaluate and manage blood‑tinged nasal discharge?

Evaluation and Management of Blood-Tinged Nasal Discharge

Begin with anterior rhinoscopy after removing any blood clots to identify the bleeding source, then treat with topical vasoconstrictors (oxymetazoline or phenylephrine) and/or nasal cautery, while simultaneously assessing for risk factors including anticoagulant use, intranasal medications, and concerning features that warrant further investigation. 1

Initial Assessment and Risk Stratification

History Taking - Key Elements

Document the following critical risk factors that modify management 1:

• Medication history: Anticoagulants, antiplatelet agents (warfarin requires INR check if supratherapeutic), intranasal corticosteroids (increase bleeding risk 2.74-fold), and intranasal drug use 1
• Medical conditions: Prior nasal/sinus surgery, nasal trauma, CPAP or nasal cannula oxygen use, personal or family history of bleeding disorders, chronic kidney or liver disease 1
• Bleeding characteristics: Unilateral versus bilateral, recurrent episodes, severity 1

Red Flags Requiring Enhanced Evaluation

In older males with blood-tinged post-nasal drip, maintain heightened suspicion for diagnoses beyond simple sinusitis - one study found 50% of such patients had conditions other than chronic sinusitis or fungal disease, compared to only 2.2% without this symptom (p<0.001). 2

Physical Examination

Anterior Rhinoscopy (Essential First Step)

Perform anterior rhinoscopy after removing any blood clots by suction or gentle nose blowing to visualize the bleeding source 1. This identifies the bleeding site in 87-93% of cases and allows for targeted therapy 1.

• Use an otoscope for visualization in young children 1
• Apply topical decongestant during examination to improve visualization 1
• Look for additional pathology: septal deviation, septal perforation, mucosal abnormalities 1

When to Perform Nasal Endoscopy

Refer for nasal endoscopy in patients with: 1

• Recurrent bleeding despite prior packing or cautery
• Recurrent unilateral nasal bleeding
• Blood-tinged discharge in older males (higher risk of non-benign pathology) 2

Acute Management

First-Line Treatment for Identified Bleeding Site

Use one or more of the following interventions 1:

1. Topical vasoconstrictors: Oxymetazoline or phenylephrine stop bleeding in 65-75% of cases 1, 3

   • Apply as intranasal spray or on cotton pledget
   • Caution: May cause cardiac or systemic complications in susceptible patients 1

2. Nasal cautery: More effective than chemical cauterization with fewer recurrences (14.5% vs 35.1%) 3

   • Electrocautery preferred over chemical methods 3
   • Requires local anesthesia in most cases 1
   • Pitfall: Excessive cautery can damage nasal lining and septum 1

3. Tranexamic acid: Topical application shows promise

   • Moderate-quality evidence shows 70% bleeding control within 10 minutes versus 30% with other agents (RR 2.35) 4
   • Oral tranexamic acid reduces re-bleeding risk from 69% to 49% over 10 days 4

If Initial Measures Fail

Apply direct pressure by pinching the soft part of the nose for 15 minutes while leaning forward 1. If bleeding persists, proceed to emergency department for nasal packing or advanced interventions 1.

Post-Treatment Care and Prevention

Preventive Measures

Educate patients on the following 1:

• Nasal humidification: Use saline sprays 1-3 times daily and bedside humidifier 1
• Avoid trauma: No nose picking, vigorous blowing, or digital manipulation 1
• Moisturizing agents: Apply nasal saline gels to prevent crusting 1

Activity Restrictions After Treatment

For at least one week after cautery 1:

• Avoid straining, lifting >10 pounds, bending over, and strenuous exercise 1
• Sleep with head elevated 1
• Avoid aspirin and ibuprofen; use acetaminophen for pain 1
• Sneeze with mouth open if packing in place 1

Warning Signs Requiring Immediate Evaluation

Instruct patients to seek care for 1:

• Return of bleeding from nose or mouth
• Fever >101°F
• Vision changes
• Shortness of breath or labored breathing
• Loss of color around nasal skin
• Facial swelling or diffuse rash

Special Considerations

Anticoagulated Patients

Do not routinely discontinue anticoagulation - these medications treat serious conditions 1. Check INR if on warfarin; supratherapeutic levels may require specialty consultation or reversal agents for severe, refractory bleeding 1.

Intranasal Corticosteroid Users

Consider cessation in patients with recurrent or severe nosebleeds, as these medications substantially increase bleeding risk 1.

Follow-Up

Document outcomes within 30 days for patients treated with packing, surgery, or arterial procedures 1. This allows assessment of treatment effectiveness and re-bleeding rates 1.